JournalsHub
.online
Find My Journal
JA

Jaffer A. Ajani

The University of Texas MD Anderson Cancer Center US

ORCID 0000-0001-9946-0629
1,740
Publications
122,585
Citations
152
H-Index
729
i10-Index
9.38
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
John S. Macdonald, Stephen R. Smalley, Jacqueline Benedetti, Scott A. Hundahl, Norman Estes +6 more
New England Journal of Medicine 2001
3,498
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial OA
Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman +24 more
The Lancet 2021
2,790
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
H. Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, G. Bodoky +15 more
The Lancet Oncology 2014
2,435
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group OA
Eric Van Cutsem, Vladimir Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla +7 more
Journal of Clinical Oncology 2006
1,929
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer OA
Ronan J. Kelly, Jaffer A. Ajani, Jarosław Kużdżał, Thomas Zander, Eric Van Cutsem +22 more
New England Journal of Medicine 2021
1,688

Publications

1,708 total

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.

Y. Janjigian, K. Shitara, J.A. Ajani, L. Shen, M. Garrido - Annals of Oncology, 2026
Cited by 1 Semantic Scholar

Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study

S. Klempner, R. Pazo-Cid, S. Lonardi, L. Swanson, M. J. Arango - ESMO gastrointestinal oncology, 2025
Cited by 12 Semantic Scholar

2106P Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): 5-year follow-up from CheckMate 648

I. Chau, J.A. Ajani, Y. Doki, J. Xu, L. Wyrwicz - Annals of Oncology, 2025
Cited by 0 Semantic Scholar

313P Characteristics, treatment patterns, and outcomes with first-line nivolumab plus chemotherapy vs chemotherapy in CheckMate 649 patients by regions

L. Shen, K. Shitara, M. Moehler, J.A. Ajani, M. Garrido - Annals of Oncology, 2025
Cited by 0 Semantic Scholar

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.

E. Elimova, J.A. Ajani, H.A. Burris, Crystal S. Denlinger, S. Iqbal - The Lancet Oncology, 2025
Cited by 12 Semantic Scholar

454P Global physician and patient-reported symptom concordance in association with quality of life in HER2-negative advanced gastric, gastroesophageal or esophageal adenocarcinoma

F. Lordick, N. Starling, J. Gu, C. Hogea, S. K. Mhatre - Annals of Oncology, 2025
Cited by 0 Semantic Scholar

417P Comparative efficacy and safety of tislelizumab (TIS) vs other anti–PD-1 treatments in first-line (1L) gastric or gastroesophageal junction cancer (GC/GEJC): A network meta-analysis (NMA)

M. A. Maqueda, J.A. Ajani, M. Moehler, K. Lee, W. Tang - Annals of Oncology, 2025
Cited by 0 Semantic Scholar

1423P Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial

E. Elimova, J.A. Ajani, H.A. Burris, C. Denlinger, S. Iqbal - Annals of Oncology, 2024
Cited by 4 Semantic Scholar

419P Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4-year (y) follow-up (FU) of CheckMate 649

L. Wyrwicz, K. Shitara, M. Moehler, J.A. Ajani, L. Shen - Annals of Oncology, 2024
Cited by 0 Semantic Scholar

1438P First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW

Y. Kang, M.A. Shah, K. Shitara, J.A. Ajani, F. Lordick - Annals of Oncology, 2024
Cited by 6 Semantic Scholar

Research Topics

Gastric Cancer Management and Outcomes (855) Esophageal Cancer Research and Treatment (544) Colorectal Cancer Treatments and Studies (216) Gastrointestinal Tumor Research and Treatment (200) Esophageal and GI Pathology (172)

Frequent Co-Authors

JO
Joseph Chao
5 joint publications
DA
David H. Ilson
5 joint publications
ER
Eric Van Cutsem
4 joint publications
TH
Thomas A. D’Amico
4 joint publications
PR
Prajnan Das
4 joint publications
PA
Paul T. Fanta
4 joint publications

Affiliations

Rutgers, The State University of New Jersey
US 2006 - 2006
Broad Institute
US 2018 - 2018
Boston University
US 2010 - 2010
Northwestern University
US 2012 - 2006
James S. McDonnell Foundation
US 2018 - 2018

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now